Vinpocetine FORTE - Instructions For Use, Price Of Tablets, Reviews

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Vinpocetine FORTE

Vinpocetine FORTE: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. Drug interactions
12. 12. Analogs
13. 13. Terms and conditions of storage
14. 14. Terms of dispensing from pharmacies
15. 15. Reviews
16. 16. Price in pharmacies

Latin name: Vinpocetine forte

ATX code: N06BX18

Active ingredient: Vinpocetine (Vinpocetine)

Manufacturer: Ozone, LLC (Russia); Sintez, JSC (Russia); Canonfarma Production, JSC (Russia)

Description and photo updated: 30.11.2018

Prices in pharmacies: from 79 rubles.

Buy

Vinpocetine FORTE is a drug that improves cerebral blood flow.

Release form and composition

Dosage form - tablets: white or white with a yellowish tinge, flat round, on one side with a line, on both sides with a bevel (in a cardboard box 1 can of 10, 20, 30, 40, 50 or 100 tablets or 1-10 blisters of 10, 20, 30 or 50 tablets and instructions for use of Vinpocetine FORTE).

Composition of 1 tablet:

• active substance: vinpocetine - 10 mg;
• excipients (composition may vary depending on the manufacturer): sodium carboxymethyl starch - 4 mg; lactose monohydrate (milk sugar) - 157 mg; microcrystalline cellulose - 20 mg; magnesium stearate - 3 mg; povidone - 6 mg.

Pharmacological properties

Pharmacodynamics

The mechanism of influence of the active substance Vinpocetine FORTE - Vinpocetine consists of the following factors: improvement of cerebral blood flow; activation of metabolism; beneficial effect on the rheological properties of blood.

The neuroprotective effect of vinpocetine is realized due to a decrease in the adverse cytotoxic effect of excitatory amino acids. As a result, blocking of Na ⁺ and Ca ²⁺ -channels and NMDA- and AMPA-receptors occurs. The substance selectively inhibits Ca ²⁺ -calmodulin-dependent-cGMP-phosphodiesterase. Increases the exchange of norepinephrine and serotonin in the brain, has an antioxidant effect, and stimulates the noradrenergic neurotransmitter system.

Improvement of microcirculation in the brain is carried out due to the following effects: inhibition of platelet aggregation and adenosine reuptake; an increase in the deformability of erythrocytes and a decrease in the pathologically increased blood viscosity.

Due to a decrease in the affinity of erythrocytes to vinpocetine, the drug promotes the transfer of oxygen into cells.

By inhibiting cerebral vascular resistance, vinpocetine selectively increases cerebral blood flow without significantly affecting systemic indicators of blood circulation, including blood pressure (blood pressure), heart rate (heart rate), cardiac output, and total peripheral vascular resistance.

The use of vinpocetine does not lead to the development of the stealing effect.

Pharmacokinetics

Vinpocetine after oral administration is rapidly absorbed in the gastrointestinal tract (absorption occurs mainly in the proximal small intestine). T _Cmax (time to reach maximum concentration) in blood plasma - 60 minutes. In the process of passing through the intestinal wall, the substance is not metabolized.

After oral administration of radioactively labeled vinpocetine to rats, the highest radioactivity was observed in the gastrointestinal tract and liver. The maximum tissue level after administration was recorded after 2–4 hours. The concentration of the substance in the tissues of the brain did not exceed its content in the blood.

The connection with plasma proteins in humans is 66%, bioavailability is about 7%. V _d (volume of distribution) - 246.7 ± 88.5 liters, which is evidence of a high binding to tissues. The total clearance is higher than the hepatic blood flow rate (66.7 and 50 L / h, respectively), thus indicating extrahepatic metabolism.

Vinpocetine easily penetrates the blood-brain barrier (including through the blood-brain barrier), as well as through the placental barrier and into breast milk (0.25% of the dose during the first hour).

The main metabolite of vinpocetine is AVA (apovincaminic acid), it accounts for 25 to 30% of the original compound. AUC (area under the concentration-time curve) of AVK after oral administration is 2 times higher than that of intravenous administration of the substance. This indicates that vinpocetine is subject to a pronounced effect of the first pass through the liver.

Other metabolites of vinpocetine: hydroxy-AVK, hydroxyvinpocetine, AVK-dioxyglycinate and their conjugates (glucuronides and / or sulfates).

Vinpocetine does not accumulate in the body, therefore, patients with impaired renal / hepatic function do not need to adjust the dosage regimen. Perhaps they will need a longer use of Vinpocetine FORTE.

With repeated use of 10 mg of vinpocetine, linear pharmacokinetics is manifested, the value of C _ss (equilibrium plasma concentration) is 2.1 ± 0.33 ng / ml.

The substance is excreted unchanged slightly (a few percent). T _1/2 (half-life) is 4.83 ± 1.29 hours.

When conducting studies with radioactively labeled vinpocetine, it was found that excretion by the intestines and kidneys occurs in a ratio of 40 ÷ 60%. AVK is excreted by glomerular filtration.

In dogs and rats, high radioactivity after administration of a radioactively labeled substance was found in bile, however, significant enterohepatic recirculation was noted.

Vinpocetine is intended for the treatment of mainly elderly patients, therefore, the slowdown in distribution and metabolism, as well as excretion, noted in this age group, especially during a long course, should be taken into account.

According to the results of clinical studies, the pharmacokinetic processes of vinpocetine in elderly patients do not differ significantly from young patients, and the accumulation of the substance and its metabolites does not occur.

Indications for use

Vinpocetine FORTE is prescribed for the symptomatic treatment of the consequences of the following neurological diseases:

• vascular vertebrobasilar insufficiency;
• ischemic stroke;
• cerebral atherosclerosis;
• vascular dementia;
• post-traumatic, hypertensive encephalopathy.

In ophthalmology, Vinpocetine FORTE is used for chronic vascular diseases of the uveal tract and retina.

In otological practice, the drug is prescribed in the following cases:

• hearing loss of the perceptual type;
• sensation of tinnitus;
• Meniere's disease.

Contraindications

Absolute:

• severe heart rhythm disturbances;
• hemorrhagic stroke in the acute phase;
• ischemic heart disease, which is severe;
• lactose intolerance, glucose-galactose malabsorption, lactase deficiency;
• pregnancy and lactation;
• age up to 18 years;
• individual intolerance to the components of the drug.

Relative (Vinpocetine FORTE tablets are used under medical supervision and periodic ECG monitoring):

• long QT syndrome;
• combination therapy with drugs that lead to prolongation of the QT interval.

Vinpocetine FORTE, instructions for use: method and dosage

Vinpocetine FORTE tablets are taken orally, after meals.

The doctor determines the dosage regimen and duration of the drug individually.

The average daily dose is 15-30 mg (3 times a day, 5-10 mg), the maximum is 30 mg (10 mg 3 times a day).

The development of a therapeutic effect is usually noted during the week of daily intake.

The average duration of treatment is 1 to 3 months.

Side effects

Possible side reactions of Vinpocetine FORTE (the following gradation in frequency is used:> 10% - very often;> 1% and 0.1% and 0.01% and <0.1% - rarely; <0.01% - very rarely):

• lymphatic system and hematopoietic system: rarely - thrombocytopenia, leukopenia; very rarely - erythrocyte agglutination, anemia, leukopenia;
• nervous system: infrequently - headache; rarely - loss of consciousness, stupor, dysgeusia, drowsiness, hemiparesis; very rarely - convulsions, tremors;
• cardiovascular system: infrequently - arterial hypotension; rarely - exertional angina, tachycardia, bradycardia, myocardial infarction / ischemia, extrasystole, arterial hypertension, palpitations, ECG changes (lengthening of the QT interval, depression of the ST segment); sensation of hot flashes; very rarely - lability of blood pressure (mainly in the direction of decrease), atrial fibrillation, arrhythmia;
• digestive system: infrequently - dry mouth, abdominal discomfort, nausea; rarely - vomiting, dyspepsia, abdominal pain, diarrhea, constipation, salivation; very rarely - stomatitis, dysphagia;
• skin and subcutaneous tissue: rarely - itching, hyperhidrosis, erythema, rash; very rarely - dermatitis;
• psyche: rarely - sleep disturbance, insomnia, anxiety; very rarely - depression, euphoria, anxiety;
• organ of hearing: infrequently - dizziness; rarely - hypoacusia, hyperacusis, tinnitus;
• organ of vision: rarely - edema of the nipple of the optic nerve; very rarely - blurred vision, conjunctival hyperemia, diplopia;
• metabolism: infrequently - hypercholesterolemia; rarely - anorexia, decreased appetite, increased triglyceride levels in the blood, diabetes mellitus; very rarely - weight gain;
• allergic reactions: rarely - urticaria; very rarely - hypersensitivity reactions;
• general disorders: rarely - weakness, asthenia, feeling of heat; very rarely - chest discomfort;
• others: rarely - change (increase / decrease) in the number of eosinophils; very rarely - an increase in lactate dehydrogenase, an increase in urea, a decrease in prothrombin time.

Overdose

• main symptoms: increased severity of dose-dependent adverse reactions;
• therapy: gastric lavage, intake of activated carbon, symptomatic treatment.

special instructions

In patients with an initially prolonged QT interval, as well as in the case of combined use with drugs that lead to an extension of the QT interval, during the period of taking Vinpocetine FORTE, electrocardiographic monitoring (ECG control) should be periodically performed.

In the case of severe cardiac arrhythmias, increased intracranial pressure, combination therapy with antiarrhythmic drugs, long QT syndrome or combination therapy with drugs that cause QT interval prolongation, Vinpocetine FORTE should be used with caution.

Influence on the ability to drive vehicles and complex mechanisms

Patients during the period of application of Vinpocetine FORTE should be careful when driving vehicles.

Application during pregnancy and lactation

Vinpocetine FORTE is not prescribed during pregnancy / lactation.

Vinpocetine crosses the histohematogenous placental barrier, but the concentration of the substance in the placenta and in the fetal blood is lower than in the blood of a pregnant woman. Teratogenic and embryotoxic effects were not identified. When conducting studies on animals with the use of high doses of the drug, the development of placental bleeding and spontaneous abortions, presumably associated with an increase in placental blood flow, was noted.

The concentration of vinpocetine in breast milk reaches 0.25% of the oral dose of the drug within an hour. The doctor, when deciding to cancel breastfeeding or refuse to take Vinpocetine FORTE, must balance the benefits for the child and the woman.

Pediatric use

Since there are no data from clinical studies, Vinpocetine FORTE is not prescribed for patients under 18 years of age.

Drug interactions

The antihypertensive effect of vinpocetine can be enhanced when combined with methyldopa, and therefore requires systematic monitoring of blood pressure.

There are no data confirming the development of interaction with centrally acting drugs, anticoagulants and antiarrhythmic drugs, however, when they are combined with Vinpocetine FORTE, care must be taken.

Analogs

Vinpocetine FORTE analogues are Vinpocetine, Vero-Vinpocetine, Vinpoton, Bravinton, Vincetin, Cavintazol, Telektol, Oxopotin, Korsavin, Cavinton, etc.

Terms and conditions of storage

Store in a place protected from light at temperatures up to 25 ° C. Keep out of the reach of children.

The shelf life is 3, 4 or 5 years (depending on the manufacturer).

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Vinpocetine FORTE

On specialized forums and websites, patients leave mostly positive reviews about Vinpocetine FORTE. They indicate the high efficiency of the drug and its affordable cost. At the same time, it is noted that in order to achieve a therapeutic effect, it is necessary to take the drug for several months.

The development of side effects is rarely reported.

Price for Vinpocetine FORTE in pharmacies

The approximate price for Vinpocetine FORTE for 30 tablets per pack is 80–91 rubles.

Vinpocetine FORTE: prices in online pharmacies

Drug name Price Pharmacy

Vinpocetine forte 10 mg tablets 30 pcs. 79 RUB Buy

Vinpocetine forte 10 mg tablets 30 pcs. RUB 80 Buy

Vinpocetine forte 10 mg tablets 30 pcs. RUB 88 Buy

Vinpocetine forte tablets 10mg 30 pcs. 93 rbl. Buy

Vinpocetine forte 10mg tablets 30 pcs. RUB 105 Buy

Vinpocetine forte Canon 10mg tablets 30 pcs. 109 RUB Buy

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!